Investing Profile

David Schenkein

VCInvestor
General Partner at GV
gv.com/team/david-schenkein/Boston, Massachusetts
Photo of David Schenkein, General Partner at GV (Google Ventures)
Your Intro Paths to David Schenkein

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Networks David is a member of
Genentech Network
74 CONNECTIONS
GV (Google Ventures) Network
55 CONNECTIONS
GV Network
47 CONNECTIONS
Wesleyan University Network
47 CONNECTIONS

Find David Schenkein on

cb
Current Investing Position
GV (Google Ventures) General Partner
Investment Range
$250K - $50.0M
Sweet Spot
$25.0M
Investments On Record
34
Current Fund Size
$8B

David Schenkein is on these Sector & Stage Rankings

David Schenkein's Investments On Record (18)

CompanyStageDateRound SizeTotal Raised
Encoded Therapeutics
Series FSep 2026$280M
Series DJul 2020$140M
$510M
Co-investors: Brendan Bulik-Sullivan (GV (Google Ventures)), Greg Yap (Menlo Ventures), Roderick Wong (RTW Investments, LP), Bryan Roberts (Venrock)
Cerevance
Series CMay 2026$20M
Series BApr 2024$47M
Series BFeb 2023$51M
Series BApr 2020$65M
$180M
Co-investors: Bill Gates (Breakthrough Energy Ventures), Laurence Barker (SV Health Investors' Dementia Discovery Fund (DDF)), Kouki Harasaki (Ikigai BioVentures), Jason Lettmann (Morgenthaler Ventures)
Mestag Therapeutics
Series UnknownMar 2026$40M
$51M
Co-investors: Issi Rozen (GV (Google Ventures)), Houman Ashrafian (SV Health Investors)
EpiBiologics
Series BJan 2026$110M
Series AJul 2023$23M
$200M
Co-investors: Anika Gupta (GV (Google Ventures)), Alexandra Cantley (Polaris Partners), Samuel Bjork (Digitalis Ventures), Alaa Halawa (Mubadala), Gaurav Aggarwal (Vivo Capital), Nisa Leung (Qiming Venture Partners), Laura Brass (MPM BioImpact)
Paradigm
Series BDec 2025$78M
Series AJan 2023$200M
$320M
Co-investors: Elena Viboch (General Catalyst), Balaji Srinivasan (Andreessen Horowitz), Niko Bonatsos (General Catalyst), Hemant Taneja (General Catalyst), Max Rimpel (Index Ventures), Bilal Zuberi (Lux Capital), Brett Cook (F-Prime Capital Partners), Stephen Knight (F-Prime Capital Partners), Jared Friedman (Y Combinator), Scott Belsky (A24), Ramnik Arora (Original Capital), Arash Ferdowsi (Dropbox), Eoghan McCabe (Spark-Local, Inc), Jay Markowitz (ARCH Venture Partners), Robert Nelsen (ARCH Venture Partners), Alaa Halawa (Mubadala), Justin Kao (DFJ Growth), Karim Atiyeh
Pelage Pharmaceuticals
Series BOct 2025$120M
Series AAug 2024$14M
Series AFeb 2024$17M
$150M
Co-investors: Richard Heyman (ARCH Venture Partners)
Treeline Biosciences
Series ASep 2025$200M
Series AApr 2021$210M
$410M
Prime Medicine
Post Ipo EquityAug 2025$5M
Series BJul 2021$200M
Series AOct 2019$120M
$320M
Co-investors: Stephen Knight (F-Prime Capital Partners), Neil Sirni (Proximity Ventures), Stephen Francis (MONTAJ), Robert Nelsen (ARCH Venture Partners)

David Schenkein's Experience

Board Member Regeneron2023 - Present
Board Member Agios Pharmaceuticals2022 - Present
General Partner GV2019 - Present
Board Member Denali Therapeutics2015 - Present
Clinical Professor of Medicine Tufts Medical Center2009 - Present
Senior Vice President, Clinical Research Senti BiosciencesPresent
Clinical Professor of Medicine Tufts MedicinePresent
General Partner GV (Google Ventures)Present
Chairperson of the Board Agios Pharmaceuticals2019 - 2022
CEO Agios Pharmaceuticals2009 - 2019
Senior Vice President, Clinical Hematology/Oncology Genentech2006 - 2009
Senior Vice President, Clinical Research Millennium Pharmaceuticals2001 - 2006

David Schenkein's Education

Wesleyan University Bachelor of Arts (B.A.) Chemistry

Investors who invest with David Schenkein

Sign in with Google →

Scouts & Angels Affiliated With David Schenkein

Sign in with Google →